On the other hand, sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently been shown to confer renal and cardiometabolic benefits in diabetic and non-diabetic subjects (69–73) but may be associated with myopathy (74) and sarcopenia (75, 76) which will be of concern to aged adults with low baseline pre-treatment skeletal muscle mass. The gene discussed is SLC5A2; the disease is sarcopenia.